ResMed, best known for its sleep apnea equipment and software, to acquire cloud-based electronic health records manager MatrixCare for $750M
Larry Dignan / ZDNet :
Context & Ripple Effects
ResMed's $750M purchase of MatrixCare is the opening move in its push from sleep apnea hardware into recurring-revenue health IT — a bet it doubled down on within a month by agreeing to acquire Propeller Health's inhaler-sensor platform for $225M. The through-line across the coverage is a device maker assembling a software layer around chronic respiratory care.
The arc closes eight years later: ResMed agrees to sell MatrixCare to PE firm Frazier for $490M in cash, booking a loss on the original price. That makes this 2018 deal the reference point for whether device-maker-owned EHR assets ever earn their keep.
First-order effects
- MatrixCare's long-term-care and home-health customers now sit inside a medical-device company whose core business is sleep apnea equipment, tying their records vendor to ResMed's device-and-software bundle strategy.
- ResMed immediately gains a cloud EHR revenue stream to offset hardware cyclicality, and follows up weeks later with the Propeller Health acquisition to extend the same digital-health playbook.
Second-order effects
- Rival device makers face pressure to match the bundle — GE HealthCare's later $2.3B purchase of Intelerad's cloud imaging and workflow software for outpatient sites shows the same device-plus-cloud-software consolidation reaching adjacent modalities.
- Standalone health-IT vendors like Relatient, which raised $100M partly to acquire Radix Health's patient-matching software, compete for the same provider workflows ResMed is trying to own.
Third-order effects
- If the pattern holds, device makers treat EHR and clinical-software acquisitions as portfolio experiments rather than permanent holdings — MatrixCare's eventual $490M sale to private equity suggests non-core software gets pruned when it doesn't compound with the hardware business.
- Health-IT assets cycle between strategic buyers and PE firms, with valuations set less by growth than by how tightly the software binds to the acquirer's devices.
The trend: Medical device makers are buying cloud clinical-software platforms to build recurring-revenue bundles around their hardware — and increasingly selling them back to private equity when the synergy case fades.